Morepen Laboratories has completed the first phase of its manufacturing capacity expansion programme ahead of schedule, increasing its installed reactor capacity for active pharmaceutical ingredients (API) and contract development and manufacturing organisation (CDMO) operations from 535 KL to 614 KL. The capacity addition is expected to strengthen Morepen Laboratories’ manufacturing readiness as the company scales […]